Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: Shanghai Henlius Biotech
Condition: Non Small Cell Lung Cancer
NCT07269782
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.